Granules India Q4 FY25 Results | 17% PAT Surge | USFDA Impact, Peptide Growth & Outlook

📊 Granules India Ltd. has reported its Q4 FY25 results with a strong 17% YoY PAT growth, despite regulatory headwinds. This video breaks down the earnings report, segment-wise performance, and management commentary. 📌 Key Highlights: Revenue: ₹11,974 Cr | +2% YoY PAT: ₹1,520 Cr | +17% YoY Gross Margin: 63.4% Strong cash flows and debt reduction USFDA remediation update and peptide CDMO expansion 💡 What You’ll Learn: How formulations are driving margin expansion Impact of USFDA warning on operations Future growth from peptides, CNS & oncology launches 📍 Sectors: Pharmaceuticals, Formulations, CDMO, API 📈 Suitable for: Long-term investors, Pharma analysts, Research-driven viewers 🔔 Subscribe for more quarterly results deep dives and fundamental analysis! 📢 Disclaimer: This video is for educational purposes only and does not constitute investment advice. Please consult a registered financial advisor before making investment decisions.